The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALLO | -56.32% | -96.67% | -49.33% | -95% |
| S&P | +16.23% | +94.45% | +14.22% | +147% |
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$3.11M | 14.8% |
| Gross Margin | -16059.09% | 0.0% |
| Market Cap | $247.17M | -49.2% |
| Market Cap / Employee | $1.08M | 0.0% |
| Employees | 229 | -1.7% |
| Net Income | -$50.94M | 23.2% |
| EBITDA | -$51.33M | 18.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $52.33M | -69.3% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $79.24M | -8.9% |
| Short Term Debt | $7.76M | 7.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -42.40% | -3.1% |
| Return On Invested Capital | -38.11% | -4.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$39.07M | 38.6% |
| Operating Free Cash Flow | -$39.03M | 38.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.14 | 0.96 | 0.73 | 0.64 | -25.55% |
| Price to Sales | 5815.41 | 5148.40 | 13621.58 | 20387.23 | 503.67% |
| Price to Tangible Book Value | 1.14 | 0.96 | 0.73 | 0.64 | -25.55% |
| Enterprise Value to EBITDA | -6.69 | -4.31 | -1.99 | -1.19 | -18.83% |
| Return on Equity | -54.1% | -55.1% | -59.6% | -55.1% | 12.63% |
| Total Debt | $92.52M | $90.76M | $88.92M | $87.00M | -7.66% |
ALLO earnings call for the period ending September 30, 2021.
ALLO earnings call for the period ending March 31, 2020.
ALLO earnings call for the period ending December 31, 2019.
ALLO earnings call for the period ending September 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
